HUP9901887A2 - Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound - Google Patents

Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound

Info

Publication number
HUP9901887A2
HUP9901887A2 HU9901887A HUP9901887A HUP9901887A2 HU P9901887 A2 HUP9901887 A2 HU P9901887A2 HU 9901887 A HU9901887 A HU 9901887A HU P9901887 A HUP9901887 A HU P9901887A HU P9901887 A2 HUP9901887 A2 HU P9901887A2
Authority
HU
Hungary
Prior art keywords
hiv protease
protease inhibitor
compositions
compound
water soluble
Prior art date
Application number
HU9901887A
Other languages
Hungarian (hu)
Inventor
Arup K. Roy
Lloyd Gary Tillman
Original Assignee
Glaxo Group Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd. filed Critical Glaxo Group Ltd.
Publication of HUP9901887A2 publication Critical patent/HUP9901887A2/en
Publication of HUP9901887A3 publication Critical patent/HUP9901887A3/en
Publication of HU228026B1 publication Critical patent/HU228026B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

A pharmaceutical formulation for oral administration comprises (1) (a) an HIV protease in inhibitor, (b) a water-soluble tocopherol derivative in a ratio of 1:0.5-1:10 w/w and optionally (c) a hydrophilic non-aqueous solvent miscible with (a); and (2) (a) an HIV protease inhibitor, and (b) \- 20% of a water-soluble tocopherol derivative in the absence of a lipophilic phase.
HU9901887A 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound HU228026B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations
PCT/EP1997/001438 WO1997035587A1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Publications (3)

Publication Number Publication Date
HUP9901887A2 true HUP9901887A2 (en) 1999-12-28
HUP9901887A3 HUP9901887A3 (en) 2000-02-28
HU228026B1 HU228026B1 (en) 2012-08-28

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901887A HU228026B1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
JP2008514714A (en) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー Pharmaceutical formulations containing vitamin ETPGS molecules solubilizing lipophilic drugs that do not exhibit significant spill inhibition and the use of such pharmaceutical formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) * 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
EP0541168B1 (en) * 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DK0727419T3 (en) * 1992-12-29 2002-06-10 Abbott Lab Intermediates for the preparation of compounds that inhibit retroviral protease
AU6122994A (en) * 1993-01-15 1994-08-15 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors and their preparation
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
CZ288312B6 (en) * 1993-12-15 2001-05-16 Merck & Co Inc HIV-protease inhibitors and pharmaceutical preparations in which they are comprised
AU699483B2 (en) * 1994-03-07 1998-12-03 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
CO4790151A1 (en) 1999-05-31
WO1997035587A1 (en) 1997-10-02
HUP9901887A3 (en) 2000-02-28
ID16781A (en) 1997-11-13
HU228026B1 (en) 2012-08-28
OA10880A (en) 2001-10-11
AR006345A1 (en) 1999-08-25
TW455491B (en) 2001-09-21
PL328916A1 (en) 1999-03-01
IL126185A (en) 2003-05-29
IL126185A0 (en) 1999-05-09
JP3117726B2 (en) 2000-12-18
JP2000500504A (en) 2000-01-18
BG102838A (en) 1999-09-30
BG64457B1 (en) 2005-03-31
MY126358A (en) 2006-09-29
PL187919B1 (en) 2004-11-30

Similar Documents

Publication Publication Date Title
HUP9901887A2 (en) Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
CA2189328A1 (en) Tocopherol compositions for delivery of biologically active agents
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
PL335575A1 (en) Hydrophilic two-component systems for use in administration of cyclosporine
AU3924895A (en) Pharmaceutical compositions
WO2002074238A3 (en) Water soluble and palatable complexes
CA2181241A1 (en) Process for Solubilizing Difficultly Soluble Pharmaceutical Actives
GB2341801B (en) Formulation
CA2271196A1 (en) Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
WO1996040784A3 (en) Method of solubilizing, purifying, and refolding protein
NO974868L (en) Preparations comprising lipophilic compounds
WO1999051271A3 (en) Compositions comprising glycol derivatives and alcohols
AU2002250914A1 (en) Method for producing an active ingredient concentrate, and an active ingredient concentrate
NO950134L (en) Formulations for orally administered pharmaceutical agents
HK1120213A1 (en) Improved hiv protease inhibitors pharmaceutical formulations
WO2001024803A3 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
AU5415699A (en) Water-soluble pharmaceutical formulation for administering sildenafil
AU2003232535A1 (en) "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors."
AU2159197A (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
MX9604004A (en) Aerosol drug formulations containing vitamin e.